Table 2.
Performance of GBM Model and Staging Systems
| Prognostic Marker | C-Statistic (95% CI) | P-value |
|---|---|---|
| Training/validation cohort (n=1899) | ||
| GBM model | 0.738 (0.717–0.758) | Ref |
| AJCC 8th edition | 0.588 (0.566–0.611) | <0.001 |
| AJCC 7th edition | 0.585 (0.564–0.605) | <0.001 |
| Test cohort (n=879) | ||
| GBM model | 0.721 (0.689–0.752) | Ref |
| AJCC 8th edition | 0.667 (0.634–0.700) | <0.001 |
| AJCC 7th edition | 0.675 (0.645–0.704) | <0.001 |
| BCLC stage | 0.603 (0.574–0.633) | <0.001 |
| CNLC stage | 0.596 (0.567–0.624) | <0.001 |
| HKLC stage | 0.637 (0.607–0.667) | <0.001 |
| CLIP classification a | 0.588 (0.547–0.629) | <0.001 |
| JIS score | 0.677 (0.645–0.708) | 0.002 |
Note:aAvailable at baseline (667/879) and compared with GBM model in test cohort.
Abbreviations: GBM, gradient boosting machine; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; CNLC, China Liver Cancer; HKLC, Hong Kong Liver Cancer; CLIP, Cancer of the Liver Italian Program; JIS, Japan Integrated Staging.